Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

U Jansen

Showing results (171-180 of 254) with videos related to

Pageof 26
Sort By:
Journal of Clinical Microbiology|November 17, 2016
Multiplex Urinary Antigen Detection for 13 Streptococcus pneumoniae Serotypes Improves Diagnosis of Pneumococcal Pneumonia in South African HIV-Infected AdultsWerner C Albrich, Michael W Pride, Shabir A Madhi, et al.
Human Vaccines & Immunotherapeutics|November 6, 2023
Safety and immunogenicity of a multivalent pneumococcal conjugate vaccine given with 13-valent pneumococcal conjugate vaccine in healthy infants: A phase 2 randomized trialMichael W Simon, Regine Bataille, Nicole S Caldwell, et al.
The Journal of Infectious Diseases|October 12, 2021
Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F Vaccine When Coadministered With a Tetanus, Diphtheria, and Acellular Pertussis VaccineJames T Peterson, Agnieszka M Zareba, David Fitz-Patrick, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 23, 2021
Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥18 YearsBrandon Essink, Charu Sabharwal, Kevin Cannon, et al.
The Journal of Infectious Diseases|December 21, 2021
A Randomized Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F VaccineEdward E Walsh, Ann R Falsey, Daniel A Scott, et al.
NPJ Vaccines|April 9, 2022
BNT162b2-elicited neutralization of Delta plus, Lambda, Mu, B.1.1.519, and Theta SARS-CoV-2 variantsJianying Liu, Yang Liu, Hongjie Xia, et al.
Nature|June 10, 2021
BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variantsJianying Liu, Yang Liu, Hongjie Xia, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|July 1, 2014
Predicting pneumococcal community-acquired pneumonia in the emergency department: evaluation of clinical parametersS M Huijts, W G Boersma, D E Grobbee, et al.
Vaccine|July 3, 2021
Persistence of hSBA titers elicited by the meningococcal serogroup B vaccine menB-FHbp for up to 4 years after a 2- or 3-dose primary series and immunogenicity, safety, and tolerability of a booster dose through 26 monthsLars Østergaard, Timo Vesikari, Shelly D Senders, et al.
Journal of Medical Virology|February 25, 2009
Quantitative human papillomavirus 16 and 18 levels in incident infections and cervical lesion developmentRachel L Winer, Tiffany G Harris, Long Fu Xi, et al.
Pageof 26

Showing results (171-180 of 254) with videos related to

Sort By:
Pageof 26
Journal of Clinical Microbiology|November 17, 2016
Multiplex Urinary Antigen Detection for 13 Streptococcus pneumoniae Serotypes Improves Diagnosis of Pneumococcal Pneumonia in South African HIV-Infected AdultsWerner C Albrich, Michael W Pride, Shabir A Madhi, et al.
Human Vaccines & Immunotherapeutics|November 6, 2023
Safety and immunogenicity of a multivalent pneumococcal conjugate vaccine given with 13-valent pneumococcal conjugate vaccine in healthy infants: A phase 2 randomized trialMichael W Simon, Regine Bataille, Nicole S Caldwell, et al.
The Journal of Infectious Diseases|October 12, 2021
Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F Vaccine When Coadministered With a Tetanus, Diphtheria, and Acellular Pertussis VaccineJames T Peterson, Agnieszka M Zareba, David Fitz-Patrick, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 23, 2021
Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥18 YearsBrandon Essink, Charu Sabharwal, Kevin Cannon, et al.
The Journal of Infectious Diseases|December 21, 2021
A Randomized Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F VaccineEdward E Walsh, Ann R Falsey, Daniel A Scott, et al.
NPJ Vaccines|April 9, 2022
BNT162b2-elicited neutralization of Delta plus, Lambda, Mu, B.1.1.519, and Theta SARS-CoV-2 variantsJianying Liu, Yang Liu, Hongjie Xia, et al.
Nature|June 10, 2021
BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variantsJianying Liu, Yang Liu, Hongjie Xia, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|July 1, 2014
Predicting pneumococcal community-acquired pneumonia in the emergency department: evaluation of clinical parametersS M Huijts, W G Boersma, D E Grobbee, et al.
Vaccine|July 3, 2021
Persistence of hSBA titers elicited by the meningococcal serogroup B vaccine menB-FHbp for up to 4 years after a 2- or 3-dose primary series and immunogenicity, safety, and tolerability of a booster dose through 26 monthsLars Østergaard, Timo Vesikari, Shelly D Senders, et al.
Journal of Medical Virology|February 25, 2009
Quantitative human papillomavirus 16 and 18 levels in incident infections and cervical lesion developmentRachel L Winer, Tiffany G Harris, Long Fu Xi, et al.
Pageof 26